Academic Journals Database
Disseminating quality controlled scientific knowledge

Naftopidil for the treatment of urinary symptoms in patients with benign prostatic hyperplasia

ADD TO MY LIST
 
Author(s): Masumori N

Journal: Therapeutics and Clinical Risk Management
ISSN 1176-6336

Volume: 2011;
Issue: default;
Start page: 227;
Date: 2011;
Original page

ABSTRACT
Naoya MasumoriDepartment of Urology, Sapporo Medical University School of Medicine, Sapporo, JapanAbstract: Naftopidil, approved only in Japan, is an α1-adrenergic receptor antagonist (α1-blocker) used to treat lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH). Different from tamsulosin hydrochloride and silodosin, in that it has higher and extremely higher affinity respectively, for the α1A-adrenergic receptor subtype than for the α1D type, naftopidil has distinct characteristics because it has a three times greater affinity for the α1D-adrenergic receptor subtype than for the α1A subtype. Although well-designed large-scale randomized controlled studies are lacking and the optimal dosage of naftopidil is not always completely determined, previous reports from Japan have shown that naftopidil has superior efficacy to a placebo and comparable efficacy to other α1-blockers such as tamsulosin. On the other hand, the incidences of ejaculatory disorders and intraoperative floppy iris syndrome induced by naftopidil may be lower than for tamsulosin and silodosin having high affinity for the α1A-adrenergic receptor subtype. However, it remains unknown if the efficacy and safety of naftopidil in Japanese is applicable to white, black and Hispanic men having LUTS/BPH in western countries.Keywords: benign prostatic hyperplasia, lower urinary tract symptoms, α1-blocker, naftopidil
Why do you need a reservation system?      Affiliate Program